Michael Caligiuri

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Evidence for discrete stages of human natural killer cell differentiation in vivo
    Aharon G Freud
    Medical Scientist Program, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 203:1033-43. 2006
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
  3. pmc Human natural killer cells
    Michael A Caligiuri
    The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, 300 West 10th St, Rm 517, Columbus, OH 43210, USA
    Blood 112:461-9. 2008
  4. pmc Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity
    Bradley W Blaser
    The Ohio State University, Comprehensive Cancer Center, A458 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1214
    Blood 108:2463-9. 2006
  5. ncbi request reprint Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 8:2812-9. 2002
  6. ncbi request reprint Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
    Bradley W Blaser
    Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA
    Blood 105:894-901. 2005
  7. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
  8. pmc IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, and Medical Genetics, the Medical Scientist Program, The Integrated Biomedical Science Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 106:2433-5. 2005
  9. ncbi request reprint Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine and School of Public Health, Columbus, Ohio 43210, USA
    Immunity 24:575-90. 2006
  10. ncbi request reprint Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma
    Jennifer L Biber
    The Ohio State Biochemistry Program, The Ohio State University, Columbus, OH 43210, USA
    Cell Immunol 216:31-42. 2002

Research Grants

  1. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2006
  2. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2005
  3. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2009
  4. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2003
  5. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2002
  6. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 1999
  7. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2001
  8. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2006
  9. Functional Characterization of MLL Gene Fusions
    Michael A Caligiuri; Fiscal Year: 2011
  10. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2000

Collaborators

Detail Information

Publications83

  1. pmc Evidence for discrete stages of human natural killer cell differentiation in vivo
    Aharon G Freud
    Medical Scientist Program, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 203:1033-43. 2006
    ....
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
    ..We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML...
  3. pmc Human natural killer cells
    Michael A Caligiuri
    The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, 300 West 10th St, Rm 517, Columbus, OH 43210, USA
    Blood 112:461-9. 2008
    ..The most recent discoveries in NK-cell receptor biology have fueled translational research that has led to remarkable results in treating human malignancy...
  4. pmc Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity
    Bradley W Blaser
    The Ohio State University, Comprehensive Cancer Center, A458 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1214
    Blood 108:2463-9. 2006
    ..Finally, we demonstrate that in the absence of donor-derived IL-15, the GVT effect is maintained. These findings thus establish a mechanism by which endogenous donor-derived IL-15 impacts the pathobiology of acute GVHD and GVT activity...
  5. ncbi request reprint Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 8:2812-9. 2002
    ..The purpose of the study is to investigate the tolerability of interleukin 2 (IL-2) after intensive chemotherapy in elderly acute myeloid leukemia (AML) patients in first complete remission (CR)...
  6. ncbi request reprint Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
    Bradley W Blaser
    Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA
    Blood 105:894-901. 2005
    ..We thus show that acute GVHD is attenuated in the absence of donor bone marrow-derived IL-15 and conclude that donor-derived IL-15 is a critical mediator of T-cell function in acute GVHD...
  7. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
    ....
  8. pmc IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, and Medical Genetics, the Medical Scientist Program, The Integrated Biomedical Science Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 106:2433-5. 2005
    ..To our knowledge, these data are the first to demonstrate in vivo activation and expansion of human T lymphocytes in response to IL-15 with concomitant exacerbation of human T-cell-mediated X-GVHD...
  9. ncbi request reprint Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine and School of Public Health, Columbus, Ohio 43210, USA
    Immunity 24:575-90. 2006
    ..Collectively, our data suggest that pro- and antiinflammatory cytokine signaling reciprocally antagonize each other in an effort to prevail in the regulation of NK cell IFN-gamma production...
  10. ncbi request reprint Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma
    Jennifer L Biber
    The Ohio State Biochemistry Program, The Ohio State University, Columbus, OH 43210, USA
    Cell Immunol 216:31-42. 2002
    ..These findings suggest that cytokine- stimulated NK cells are able to promote systemic inflammation via the induction of STAT4-responsive genes other than IFN-gamma or TNF-alpha...
  11. pmc DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication
    Susan P Whitman
    Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Blood 112:2013-6. 2008
    ..Within the majority of MLL-PTD AML is a mechanism in which DNA hypermethylation silences a TSG that, together with MLL-PTD, can contribute further to aberrant chromatin remodeling and altered gene expression...
  12. pmc The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
    Susan P Whitman
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 106:345-52. 2005
    ....
  13. pmc Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 116:788-92. 2010
    ..Our results indicate that WT1mut CN-AML represents a distinct entity with poor treatment response across age groups. This study has been registered at www.clinicaltrials.gov as #NCT00900224...
  14. pmc In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis
    Martin Guimond
    Department of Molecular Virology, The Ohio State University, Columbus, OH43210, USA
    J Immunol 184:2769-75. 2010
    ..In summary, a CD11c(hi) DC population expressing IL-15 is required to maintain NK cell homeostasis under conditions of normal cellularity and also is required to mediate Flt3 ligand-induced NK cell expansion in vivo...
  15. pmc Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations
    Adrienne M Dorrance
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43220, USA
    J Clin Invest 116:2707-16. 2006
    ....
  16. pmc Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Christian Langer
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Suite A434 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH 43210, USA
    J Clin Oncol 27:3198-204. 2009
    ..CONCLUSION MN1 expression independently predicts outcome in CN-AML patients. The MN1 gene- and microRNA-expression signatures suggest biologic features that could be exploited as therapeutic targets...
  17. ncbi request reprint BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
    Claudia D Baldus
    The Ohio State University, Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 102:1613-8. 2003
    ..7, 2.6, and 2.2. We conclude that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics...
  18. pmc Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells
    Brian Becknell
    Medical Scientist Program, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:2481-7. 2007
    ..Thus, Hlx expression in activated NK cells temporally controls and limits the monokine-induced production of IFN-gamma, in part through the targeted depletion of STAT4...
  19. pmc The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development
    Il Kyoo Park
    Human Cancer Genetics Program, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2470-7. 2009
    ....
  20. pmc Tumor growth impedes natural-killer-cell maturation in the bone marrow
    John O Richards
    Division of Cancer Immunology, Department of Pathology, The Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH 43210, USA
    Blood 108:246-52. 2006
    ..Our data demonstrate that tumor growth can impede functional maturation of NK cells, most likely by interrupting the requisite IL-15 signaling pathway...
  21. ncbi request reprint Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation
    Rossana Trotta
    Department of Molecular Virology, Immunology, and Medical Genetics, Colelge of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:3011-8. 2005
    ....
  22. ncbi request reprint Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35
    Flavia Pichiorri
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 12:3494-501. 2006
    ..We have generated a chimeric FHIT-containing adenovirus composed of Ad5 and the group B adenovirus called F35 with which we have been able to efficiently infect hematopoietic cells...
  23. ncbi request reprint Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12
    Robin Parihar
    Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Cancer Res 65:9099-107. 2005
    ....
  24. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  25. ncbi request reprint The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Cell 8:355-68. 2005
    ..Thus, functional inactivation of PP2A is essential for BCR/ABL leukemogenesis and, perhaps, required for blastic transformation...
  26. pmc Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:4595-602. 2008
    ....
  27. ncbi request reprint Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study
    Charles F Eisenbeis
    Division of Hematology Oncology, Comprehensive Cancer Center, and Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 10:6101-10. 2004
    ..We also conducted a phase I trial of IL-2 and rituximab in relapsed B-NHL to study whether expansion of natural killer (NK) cells and enhanced cellular cytotoxicity could be safely accomplished in vivo...
  28. pmc IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:2348-55. 2010
    ....
  29. pmc Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes
    Claudia D Baldus
    Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 101:3915-20. 2004
    ..Our results highlight the value of molecularly dissecting leukemic cells with complex karyotypes...
  30. ncbi request reprint Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
    Li Yu
    Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, Ohio 43210, USA
    Nat Genet 37:265-74. 2005
    ..We also identified Idb4 as a putative tumor-suppressor gene that is methylated in most mouse and human leukemias but in only a minority of other human cancers...
  31. pmc TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells
    Rossana Trotta
    Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    J Immunol 181:3784-92. 2008
    ..This effect was accentuated in cells overexpressing SMAD3. Collectively, our results indicate that TGF-beta inhibits CD16-mediated human NK cell IFN-gamma production and ADCC, and these effects are mediated via SMAD3...
  32. ncbi request reprint The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry
    Sherif S Farag
    The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:876-84. 2006
    ..There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing...
  33. ncbi request reprint A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer
    Manisha H Shah
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, USA
    Clin Cancer Res 12:3993-6. 2006
    ..To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study...
  34. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  35. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
  36. pmc FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Susan P Whitman
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 116:3622-6. 2010
    ..FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches...
  37. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
    ..5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD...
  38. ncbi request reprint Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
    Syed Rehan A Hussain
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 13:2144-50. 2007
    ..Mcl-1 has also been reported to mediate resistance to rituximab in CLL. We therefore investigated whether direct reduction of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab...
  39. pmc Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells
    Don M Benson
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 113:2706-14. 2009
    ..The effect results at least in part via enhanced MAPK-mediated modulation of p27 and CDK4. Collectively the data reveal a novel mechanism by which SCF enhances cellular proliferation in combination with IL-2/15 in primary human NK cells...
  40. pmc A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
    Aruna Mani
    Department of Internal Medicine, Ohio State University Medical Center, Columbus, 43210, USA
    Breast Cancer Res Treat 117:83-9. 2009
    ..However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-gamma transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit...
  41. ncbi request reprint Transcriptional control of human T-BET expression: the role of Sp1
    Jianhua Yu
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Eur J Immunol 37:2549-61. 2007
    ....
  42. pmc The PP2A inhibitor SET regulates natural killer cell IFN-gamma production
    Rossana Trotta
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 204:2397-405. 2007
    ..Thus, SET expression is essential for suppressing PP2A phosphatase activity that would otherwise limit NK cell antitumoral and/or antiinflammatory functions by impairing NK cell production of IFN-gamma...
  43. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
    ....
  44. pmc FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43240, USA
    Blood 111:1552-9. 2008
    ....
  45. pmc Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:2364-73. 2008
    ..Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug...
  46. ncbi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
    ..A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)...
  47. ncbi request reprint Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions
    Clara D Bloomfield
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 12:3564s-71s. 2006
    ....
  48. pmc Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
    Michael D Radmacher
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Suite A455 Starling Loving Hall, 320 West Tenth Ave, Columbus, OH 43210, USA
    Blood 108:1677-83. 2006
    ..Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML...
  49. ncbi request reprint Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector
    Brian Becknell
    Medical Scientist Program, Integrated Biomedical Graduate Program, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    J Immunol Methods 296:115-23. 2005
    ....
  50. ncbi request reprint A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies
    Li Yu
    Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Genomics 84:647-60. 2004
    ..Luciferase assays using NotI-EcoRV clones confirmed that the library is enriched for promoter sequences. Thus, this library will support future genetic and epigenetic studies in mouse models...
  51. ncbi request reprint A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells
    Aharon G Freud
    Department of Molecular Virology, Immunology, and Medical Genetics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio 43210, USA
    Immunity 22:295-304. 2005
    ..The data identify a new NK precursor and support a model of human NK development in which BM-derived CD34dimCD45RA(+)beta7bright HPCs reside in LN where endogenous cytokines drive their differentiation to CD56bright NK cells in vivo...
  52. ncbi request reprint Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:437-43. 2006
    ..1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy...
  53. ncbi request reprint Human natural killer cell development and biology
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, A312 Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
    Blood Rev 20:123-37. 2006
    ..In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer...
  54. ncbi request reprint CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity
    Todd A Fehniger
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 101:3052-7. 2003
    ..These data show a dynamic interaction between innate and adaptive human lymphocytes and emphasize the importance of studying interactions between immune components to understand the immune response as a whole...
  55. pmc TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:5558-67. 2009
    ..Collectively, our data suggest that TSC-22 normally contributes to the regulation of HPC function and is a putative tumor suppressor gene that is hypermethylated and silenced in T or NK LGL leukemia...
  56. ncbi request reprint Immunologic approaches to acute leukemia in the elderly
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Semin Hematol 43:118-25. 2006
    ..In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia...
  57. ncbi request reprint IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice
    Julie E Dierksheide
    Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
    Blood 105:1558-65. 2005
    ..Further, our data indicate that IFNG genotype may provide valuable information for both identifying transplant recipients at greater risk for PTLD and developing preventive and curative strategies...
  58. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
    ..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
  59. ncbi request reprint Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, USA
    J Natl Cancer Inst 96:1447-57. 2004
    ..We evaluated the effect of depsipeptide, a histone deacetylase inhibitor, on EBV-positive lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines in a mouse model and explored its mechanism of action in vitro...
  60. ncbi request reprint Interleukin-2 and interleukin-15: immunotherapy for cancer
    Todd A Fehniger
    Department of Internal Medicine, Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Cytokine Growth Factor Rev 13:169-83. 2002
    ..The growing basic and pre-clinical evidence demonstrating that IL-15 may be useful in immunotherapy approaches to cancer is also presented...
  61. ncbi request reprint In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells
    Megan A Cooper
    Department of Internal Medicine, Division of Hematology Oncology, The James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Blood 100:3633-8. 2002
    ..These results show conclusively that IL-15 is required for mature NK cell survival in vivo and suggest that IL-15 mediates its effect on NK cell survival by means of Bcl-2...
  62. pmc Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma
    Sri Vidya Kondadasula
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, The Arthur G James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH, USA
    Blood 111:4173-83. 2008
    ..These data suggest that dual recruitment of FcgammaRIIIa and the IL-12R to lipid raft microdomains allows for enhanced activation of downstream signaling events that lead to IFN-gamma production...
  63. pmc Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis
    Anna M Eiring
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, USA
    Blood 111:816-28. 2008
    ..Thus, the complexity of the mRNA/RBP network, together with the discovery of E2F3 as an hnRNP-A1-regulated factor, outlines the relevant role played by RBPs in posttranscriptional regulation of CML development and progression...
  64. ncbi request reprint Cytokine therapy for cancer: antigen presentation
    Sameek Roychowdhury
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Cancer Treat Res 123:249-66. 2005
  65. ncbi request reprint Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
    Jonathan E Kolitz
    Don Monti Division of Oncology and Division of Hematology, Department of Medicine, North Shore University Hospital, New York University School of Medicine, NY 11030, USA
    J Clin Oncol 22:4290-301. 2004
    ..Clinical rather than pharmacokinetic end points were used to develop two induction therapies containing drugs susceptible to Pgp-mediated efflux and associated with comparable toxicities at the maximum-tolerated doses...
  66. ncbi request reprint What does it take to make a natural killer?
    Francesco Colucci
    Cytokines and Lymphoid Development Unit, Department of Immunology, Pasteur Institute, 25 rue du Dr Roux, 75724 Paris, France
    Nat Rev Immunol 3:413-25. 2003
    ..An improved knowledge of NK-cell development in mice and humans might be useful to harness the power of these natural killers in the clinic to fight autoimmune diseases, infection and cancer...
  67. ncbi request reprint New developments in anti-tumor efficacy and malignant transformation of human natural killer cells
    Jeffrey B VanDeusen
    Division of Human Cancer Genetics, Department of Molecular Virology, Immunology, and Medical Genetics, The James Cancer Hospital and The Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Curr Opin Hematol 10:55-9. 2003
    ..This brief review will summarize current directions in NK cell immune therapy and give an update on the classification and treatment of NK malignancies...
  68. ncbi request reprint Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation
    Natallia Mikhalkevich
    David H Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Immunol 176:1553-60. 2006
    ..Thus, the IL-4Ralpha level on naive CD4 T cells is genetically controlled by Hlx and determines the ratio of Th1 and Th2 cell differentiation...
  69. ncbi request reprint Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15
    Bradley W Blaser
    The Ohio State University Medical Center, The Ohio State University, 458 A Starling Loving Hall, 320 W 10th Avenue, Columbus, OH 43210 1214, USA
    Best Pract Res Clin Haematol 19:281-92. 2006
    ..This article examines some of the challenges that limit autologous antileukemia immunity as well as some possible immunotherapeutic approaches that may help control leukemic relapse following autologous SCT...
  70. ncbi request reprint Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  71. ncbi request reprint Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection
    Khuong B Nguyen
    Deparment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
    J Immunol 169:4279-87. 2002
    ....
  72. ncbi request reprint Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories
    Richard L Schilsky
    University of Chicago, Biological Sciences Division, Illinois 60637, USA
    Clin Cancer Res 8:943-8. 2002
  73. ncbi request reprint A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khuda D Khan
    American Health Network Oncology Hematology, Indianapolis, Indiana, USA
    Clin Cancer Res 12:7046-53. 2006
    ..Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted...
  74. ncbi request reprint Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?
    Charles F Eisenbeis
    Clin Cancer Res 9:5810-2. 2003
  75. ncbi request reprint Cancer T cell therapy expands
    Brian Becknell
    Nat Med 9:257-8. 2003
  76. ncbi request reprint Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox
    Danilo Perrotti
    J Clin Oncol 22:582-4. 2004
  77. ncbi request reprint Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia
    Adolfo A Ferrando
    Department of Pediatric Oncology, Dana Farber Cancer Institute Harvard School of Public Health, 44 Binney Street, Mayer 630, Boston 02115, MA, USA
    Lancet 363:535-6. 2004
    ..Furthermore, our findings lead to questions about whether stem-cell transplantation in first remission is necessary for effective treatment of patients in the low-risk subgroup of patients with TLX1 oncogene expression...
  78. ncbi request reprint Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
    Takehito Igarashi
    Hematology Branch, Flow Cytometry Core Facility, National Heart, Lund, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Blood 104:170-7. 2004
    ..These data suggest immunotherapeutic strategies that use KIR-incompatible allogeneic NK cells might have superior antineoplastic effects against solid tumors compared with approaches using autologous NK cells...
  79. ncbi request reprint AIDS-associated malignancies
    Manisha H Shah
    The Ohio State University, Columbus 43210, USA
    Cancer Chemother Biol Response Modif 21:717-46. 2003
  80. ncbi request reprint BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2
    Danilo Perrotti
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Genet 30:48-58. 2002
    ..Our results indicate that BCR-ABL regulates the expression of C/EBPalpha by inducing hnRNP E2-which inhibits the translation of CEBPA mRNA...
  81. ncbi request reprint Chronic lymphocytosis of functionally immature natural killer cells
    Anthony R French
    Division of Pediatric Rheumatology, Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA
    J Allergy Clin Immunol 120:924-31. 2007
    ..NK cells in this mouse were both phenotypically and functionally immature and accumulated in the bone marrow at a stage at which constitutive NK cell proliferation occurs in wild-type mice...
  82. ncbi request reprint Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations
    Stefan Fröhling
    Department of Internal Medicine III, University Hospital of Ulm, Robert Koch Strasse 8, 89081 Ulm, Germany
    Genes Chromosomes Cancer 42:427-32. 2005
    ..Loss of a critical segment of 9q, most likely in 9q22, and disruption of CEBPA function possibly cooperate in the pathogenesis of del(9q) AML...
  83. pmc Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720
    Maria R Baer
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Clin Oncol 26:4934-9. 2008
    ..Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML)...

Research Grants29

  1. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2006
    ..Ultimately, we believe insights gained by the experiments proposed in this application will further our understanding of leukemogenesis and open up new therapeutic options for this subset of AML patients with a poor prognosis. ..
  2. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2005
    ..abstract_text> ..
  3. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2009
    ..abstract_text> ..
  4. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2003
    ..Ultimately, we believe insights gained by the experiments proposed in this application will further our understanding of leukemogenesis and open up new therapeutic options for this subset of AML patients with a poor prognosis. ..
  5. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2002
    ..Ultimately, we believe insights gained by the experiments proposed in this application will further our understanding of leukemogenesis and open up new therapeutic options for this subset of AML patients with a poor prognosis. ..
  6. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 1999
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  7. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2001
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  8. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2006
    ..abstract_text> ..
  9. Functional Characterization of MLL Gene Fusions
    Michael A Caligiuri; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: Collectively, we believe this work will reveal insights as to how to best treat patients with Acute Myelogenous Leukemia and the Partial Tandem Duplication of the Mixed Lineage Leukemia Gene. ..
  10. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2000
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  11. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2002
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  12. IL-15 Characterization Through Experimental Immunology
    Michael Caligiuri; Fiscal Year: 2007
    ..abstract_text> ..
  13. Functional Characterization of MLL Gene Fusions
    Michael A Caligiuri; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Collectively, we believe this work will reveal insights as to how to best treat patients with Acute Myelogenous Leukemia and the Partial Tandem Duplication of the Mixed Lineage Leukemia Gene. ..
  14. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE: Collectively, we believe this work will reveal insights as to how to best treat patients with Acute Myelogenous Leukemia and the Partial Tandem Duplication of the Mixed Lineage Leukemia Gene. ..
  15. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE: Collectively, we believe this work will reveal insights as to how to best treat patients with Acute Myelogenous Leukemia and the Partial Tandem Duplication of the Mixed Lineage Leukemia Gene. ..
  16. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2005
    ..Ultimately, we believe insights gained by the experiments proposed in this application will further our understanding of leukemogenesis and open up new therapeutic options for this subset of AML patients with a poor prognosis. ..
  17. Functional Characterization of MLL Gene Fusions
    Michael Caligiuri; Fiscal Year: 2004
    ..Ultimately, we believe insights gained by the experiments proposed in this application will further our understanding of leukemogenesis and open up new therapeutic options for this subset of AML patients with a poor prognosis. ..
  18. IL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGY
    Michael Caligiuri; Fiscal Year: 1999
    ....
  19. Functional Characterization of MLL Gene Fusions
    Michael A Caligiuri; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Collectively, we believe this work will reveal insights as to how to best treat patients with Acute Myelogenous Leukemia and the Partial Tandem Duplication of the Mixed Lineage Leukemia Gene. ..